[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Actinic Keratosis pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 59 pages | ID: A9E745079DF4EN

US$ 1,599.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
2020 Actinic Keratosis PIPELINE HIGHLIGHTS
Actinic Keratosis is one of the widely researched conditions during 2020 with 10 companies actively focusing on realizing pipeline’s potential. Development of Actinic Keratosis medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Actinic Keratosis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Actinic Keratosis.

Good progress is anticipated during 2020 and 2021 with Actinic Keratosis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Actinic Keratosis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
The “Actinic Keratosis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Actinic Keratosis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Actinic Keratosis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Actinic Keratosis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Actinic Keratosis DRUG PROFILES
Actinic Keratosis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators
Actinic Keratosis COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Actinic Keratosis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Actinic Keratosis. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 10 Actinic Keratosis companies including company overview, key snapshot, contact information, and their strategies on accelerating Actinic Keratosis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- AmDerma Pharmaceuticals LLC, Amryt Pharma, Athenex Inc, G&E Corporation, MedC Biopharma Ltd, Nanology LLC, Neonc Technologies Inc, OJER Pharma, Singh Biotechnology LLC, Vidac Pharma Ltd

  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Actinic Keratosis
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners

1.1 Actinic Keratosis- Disease overview
1.2 Actinic Keratosis- Market Size
1.3 Actinic Keratosis- Companies Involved


2.1 Actinic Keratosis Pipeline by Phase
2.2 Actinic Keratosis Pipeline by Mechanism of Action
2.3 Actinic Keratosis Pipeline by Route of Administration
2.4 Actinic Keratosis Pipeline- New Molecular Entities
2.5 Actinic Keratosis Pipeline- Orphan Drug Designation/ Special Designation


3.1 Current Status
3.2 Actinic Keratosis Drug Snapshot
3.3 Actinic Keratosis Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 AmDerma Pharmaceuticals LLC Actinic Keratosis Pipeline Insights and Clinical Trials
4.2 Amryt Pharma Actinic Keratosis Pipeline Insights and Clinical Trials
4.3 Athenex Inc Actinic Keratosis Pipeline Insights and Clinical Trials
4.4 G&E Corporation Actinic Keratosis Pipeline Insights and Clinical Trials
4.5 MedC Biopharma Ltd Actinic Keratosis Pipeline Insights and Clinical Trials
4.6 Nanology LLC Actinic Keratosis Pipeline Insights and Clinical Trials
4.7 Neonc Technologies Inc Actinic Keratosis Pipeline Insights and Clinical Trials
4.8 OJER Pharma Actinic Keratosis Pipeline Insights and Clinical Trials
4.9 Singh Biotechnology LLC Actinic Keratosis Pipeline Insights and Clinical Trials
4.10 Vidac Pharma Ltd Actinic Keratosis Pipeline Insights and Clinical Trials



6.1 Sources and Methodology
6.2 Contact Information

More Publications